At the news
? BEARISHIMPACT 5/10 S-3/A filed Nov 10, 2026 at 18:20 ET
ABVC BioPharma filed Amendment No. 1 to its S-3 shelf registration statement, registering up to $100 million in securities (common stock, preferred stock, warrants, subscription rights, debt securities, and units). The filing responds to SEC comments and does not register additional securities. The company's public float was $22.2 million as of November 9, 2026, limiting primary common stock sales to one-third of that amount in any 12-month period under General Instruction I.B.6. The shelf signals potential future dilution and capital-raising flexibility for a clinical-stage biopharma with going concern risks.
- Shelf registration of up to $100,000,000 in securities (common stock, preferred stock, warrants, subscription rights, debt securities, units).
- Public float of $22,176,178 as of November 9, 2026, limiting primary common stock sales to one-third of public float ($7.4M) in any 12-month period.
- 26,976,625 shares of common stock outstanding as of November 9, 2026.
- Company is a clinical-stage biopharma with no approved products, substantial doubt about going concern, and recent financial restatements.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access